In one paragraphArticle in Molecular cancer research : MCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Danielle A ScottDepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-2461-9812 Souvik SealDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-3268-610X Laura SpruillDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0003-1895-5203 Jaclyn DunneDepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0009-0005-0258-1368 Graham ColditzDivision of Public Health Sciences, Department of Surgery, Institute for Public Health, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-7307-0291 Anand S MehtaDepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-9846-9389 Richard R DrakeDepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-6285-6440 Marvella E FordDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-7246-9938 Peggi M AngelDepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, South Carolina.ORCID 0000-0002-4436-555X Funding
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Jian Ouyang · 2009 to 2026
$42.7MSOUTH CAROLINA COBRE IN OXIDANTS, REDOX BALANCE AND STRESS SIGNALINGP20GM103542 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TEW, KENNETH D. · 2012 to 2020
$20.2MThe role of SMAD1 and SATB2 in colon patterningP20GM130457 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Hailong Zhang · 2020 to 2026
$18.7MDeciphering the Glycan Code in Human Alzheimer’s Disease BrainR01AG078702 · NIA · UNIVERSITY OF KENTUCKY · PI Peggi M Angel, Sean Curtis Bendall · 2022 to 2026
$3.8MCollagen Sequence Variants in Racial Disparities of Breast CancerR01CA253460 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M · 2020 to 2024
$2.6MBruker scimaX™ Magnetic Resonance Mass SpectrometerS10OD030212 · OD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M · 2021 to 2021
$1.7MOrbitrap Fusion Lumos ETD Mass SpectrometerS10OD025126 · OD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BALL, LAUREN ELIZABETH · 2018 to 2018
$991kOrbitrap Mass SpectrometerS10OD010731 · OD · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BALL, LAUREN ELIZABETH · 2012 to 2012
$600kSpatial Proteomics of osteoarthritis in bones to uncover disease progressionR21AR084303 · NIAMS · BUCK INSTITUTE FOR RESEARCH ON AGING · PI ALLISTON, TAMARA N, ANGEL, PEGGI M · 2024 to 2024
$457kSpatial stromal proteomic biosignatures of DCIS risk and progressionR21CA286287 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M · 2024 to 2024
$380kCellular Sources of Pathological Stromal VariantsR21CA263464 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M · 2021 to 2022
$376kBIODEGRADABLE POLYMERS FOR ORTHOPEDIC APPLICATIONSF32AR008430 · NIAMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI PARKS-WYATT, MICHELLE E · 1996 to 1997
–Hollings Cancer Center, Medical University of South Carolina (Hollings Cancer Center) P30CA138313National Cancer Institute (NCI) R01CA253460National Cancer Institute (NCI) R21CA263464National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R21AR08430National Institute of General Medical Sciences (NIGMS) 5P20GM130457National Institute of General Medical Sciences (NIGMS) P20GM103542NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA253460NCI NIH HHS R21 CA263464NCI NIH HHS R21 CA286287NIAMS NIH HHS F32 AR008430NIAMS NIH HHS R21 AR084303NIA NIH HHS R01 AG078702NIGMS NIH HHS P20 GM103542NIGMS NIH HHS P20 GM130457NIH HHS S10 OD010731NIH HHS S10 OD025126NIH HHS S10 OD030212NIH Office of the Director (OD) S10OD030212
6 · The paper itselfAbstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer lacking targeted therapies. Although aberrant N-glycosylation is a hallmark of malignancy, the specific roles of core-fucosylated (CF) and outer arm-fucosylated (OAF) N-glycans in TNBC progression and patient survival remain underexplored. This study utilized multiplexed glycomics by matrix-assisted laser desorption/ionization imaging mass spectrometry to spatially profile 348 N-glycans in 59 TNBC tumors with clinical characteristics including survival data. Spatial analysis revealed distinct localization patterns of CF and OAF isomers within tumor microenvironments. Strikingly, OAF glycans, but not CF, were strongly associated with tumor stage, with expression increasing from stage I to III and then declining in stage IV. Furthermore, 68 N-glycans were significantly associated with survival outcomes; 36 (52%) of these were OAF-modified, including polylactosamine structures previously linked to metastasis in breast cancer. High expression of OAF polylactosamines correlated with poor prognosis and was detectable in early-stage TNBC tumors, underscoring their potential as prognostic biomarkers. IMPLICATIONS: These findings demonstrate that OAF N-glycans are dynamic, structure-specific markers of TNBC progression and survival, and their early detection and strong prognostic value highlight potential utility in patient stratification and personalized therapy.
Indexed as
FucosePolysaccharidesTriple Negative Breast NeoplasmsBiomarkers, TumorFemaleGlycomicsGlycosylationHumansMiddle AgedPrognosisBiomarkers, TumorFucosePolysaccharides
Identifiers
PMID40965337
PMCPMC12670077
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390